Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma
ASCO 2019 Dr. Richardson on Isatuximab | Int Myeloma Fn
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma | Haematologica
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
OncLive - Register Today for our next online broadcast: http://www.onclive.com/link/7700 SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
OPTIMISMM Trial - Slideset Download - Clin Onc June 2018 | CCO
Phase II Trials of Pomalidomide and Dexamethasone in Combination with Either Cyclophosphamide or Bortezomib in Relapsed or Refractory MM | Research To Practice
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
ICARIA-MM Study Updates| Int'l Myeloma Foundation
Pomalidomide with dexamethasone direct anti-myeloma effects under... | Download Scientific Diagram
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers | Journal of Cancer Research and
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma pts - YouTube
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis - Clinical Lymphoma, Myeloma and Leukemia
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma - ScienceDirect
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies - Szabo - eJHaem - Wiley Online Library
Trials
![PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c2d9ab11b5739b401b8d3d2d135f5d895e4a8519/14-Figure3-1.png "PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar")
PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
